Specifically, 54.2% of female patients in low—expression miR-4297 group had IDH 1/2 mutation, whereas only 20.8% of subjects in high - expression miR-4297 group were IDH1/2-mutant gliomas (Table 2). The gene discussed is IDH1; the disease is central nervous system cancer.